Drug intelligence / Profile preview

spcd-4-79

Development stage: Preclinical
Lead developer: Supercede Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

SPCD-4-79 is an orally bioavailable, low molecular weight small molecule developed by Supercede Therapeutics as a potential treatment for obesity. Its mechanism of action is inhibition of both isoforms of the Activin receptor type II (ACTRIIA and ACTRIIB). Preclinical studies in diet-induced obesity (DIO) mice have shown SPCD-4-79 leads to significant reductions in fat mass, liver mass, liver fat, and overall body weight, both as a single agent and in combination with GLP-1 receptor agonists such as semaglutide. The compound is currently at the preclinical development stage and has not yet entered clinical trials[2][10].

Other names: SPCD-4-79SPCD4-79SPCD 4-79

Targets

ACVR2A (Activin receptor type 2A)ACVR2B (Activin receptor type IIB)

Beyond the preview

Go deeper on spcd-4-79.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on spcd-4-79.

Explore the full profile